HOME - LATEST NEWS - Corporate - Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection

LATEST NEWS

Corporate

Corporate

2021.05.25

Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection

(May 25th, 2021, Taipei) Lumosa Therapeutics is pleased to announce today the execution of an exclusive distribution agreement with PrJSC Pharmaceutical Firm Darnitsa (“Darnitsa”) for LT1001 in Ukraine. Darnitsa is one of the largest pharmaceutical companies in Ukraine. The company develops, manufactures, and markets generic, prescription, and over-the-counter products in several therapeutic areas including pain management. According to the agreement, Darnitsa is responsible for the registration, sales, and marketing of LT1001 in Ukraine, and Lumosa will supply LT1001 drug product. Lumosa is looking forward to working with Darnitsa to bring this unique product to the Ukrainian analgesic market, as well as gaining possible access to the Eastern European countries and Commonwealth of Independent States. 
LT1001 (Naldebain®) is a long-duration analgesic effect up to 7 days through a single IM injection in the post-operative setting without causing dependence potential and respiratory depression. LT1001 was approved in Taiwan in 2017 and then in Singapore in 2020. A Phase 3 pivotal trial is currently on-going in China and the development the USA is still under progress.